This was a multicenter, open-label, randomized, crossover trial in subjects with MS who were
already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. The trial was
designed to assess subject preference for Kemstro or conventional baclofen. At Visit 1,
subjects were screened, and if qualified, were randomly assigned to one of two following
treatment sequences: Kemstro/conventional baclofen or conventional baclofen/Kemstro.
- stable dose of baclofen
- not stable dosing